Disconnect between in vitro and in vivo efficacy of the MPS1 inhibitor NTRC 0066-0 against glioblastoma

Mark C. de Gooijer(Manchester Academic Health Science Centre), Olaf van Tellingen(Oncode Institute)
Cellular Oncology
February 16, 2026
Cited by 0


Related Papers